Orchestra BioMed Holdings, Inc.
OBIO · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | – | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | – | $0 | $0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 3% | -3.7% | 243.1% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 94.3% | 94.5% | 94.9% | 77.1% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -2,349.8% | -2,302.2% | -2,151.2% | -6,558.5% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -2,419% | -2,316.1% | -2,160.7% | -6,385.4% |
| EPS Diluted | -0.4 | -0.5 | -0.49 | -0.42 |
| % Growth | 20% | -2% | -16.7% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |